Immunotherapy PCa VL

Immunotherapy Update

Details
Immunotherapy Update Neal Shore, MD gives an update on immunotherapy for prostate cancer, explaining the rationale for this treatment and reviewing current clinical trial results as well as ongoing trials. Neal D. Shore, MD, FACS Carolina Urologic Research Center

Early Identification of Metastatic Disease in PCa

Details
Early Identification of Metastatic Disease in PCa Paul Sieber, MD presents recommendations from a multidisciplinary group which identified optimal strategies for early identification of metastases in patients with prostate cancer. Paul Sieber, MD Lancaster Urology Click HERE to read the abstract

Early Identification of Metastatic PCa+

Details
Early Identification of Metastatic PCa+ Tom Keane, MBBCh, FRCSI, FACS reviews the article, Challenges and recommendations for early identification of metastatic disease in prostate cancer . Thomas E. Keane, MBBCh, FRCSI, FACS Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA Click HERE to read the abstract. Click HERE to read a commentary...

Immune Response to Sipuleucel-T for mCRPC

Details
Clinical and biologic factors for immune response to Sipuleucel-T for mCRPC Mehmet F. Hepgur, MD Click HERE to view the poster from this session

Power of the Immune System in Combination Therapy

Details
State-of-the-Art Lecture: Unleashing the power of the immune system through combination therapy James L. Gulley, MD, PhD, FACP Click HERE to read an exclusive report by a UroToday medical writer

Impact of Prior Docetaxel on Sipuleucel-T

Details
SUO 2013 - Impact of Prior Docetaxel on Sipuleucel-T Product Parameters in PROCEED Patients Click HERE to read the abstract and poster Oliver Sartor, MD Tulane Cancer Center

Individualizing Care in mCRPC

Details
Challenges and Practicalities in Individualizing Care of Patients with mCRPC Leanne Schimke, MSN, CRNP, CUNP Lancaster Urology

CRPC - The New Frontier

Details
CRPC - The New Frontier Leanne Schimke, MSN, CRNP, CUNP Lancaster Urology

Detection of mCRPC in ADT Naïve

Details
Podcast with Dr. Adam Kibel, summarizing the poster "Metastatic Disease Detection is an Important Cause of Screen Failures in a Phase II Trial Evaluating the Optimal Sequence of Androgen Deprivation Therapy and Sipuleucel-T in Hormone-Naïve Patients with Biochemically-Recurrent Prostate Cancer (BRPC)" presented at the European Cancer Congress (ECCO) in Amsterdam, September 29 to October 1, 2013 Th...

Immunotherapy in Pca+

Details
Understanding and Implementing Immunotherapy for Prostate Cancer Dr. Charles Drake discusses immunotherapy for prostate cancer, including three specific immunotherapies in various stages of clinical development, cancer "vaccines", and combining immunotherapy with other treatments. Charles G. Drake, MD, PhD - BIO